preDiCT

Many drugs fail to reach the market because of side effects on the heart. The principal objective of this proposal is to create an advanced computational technology for in silico assessment of the efficacy and safety of specific drugs [ICT-2007.5.3(c) (3)], i.e. an open environment comprising validated computational models, tools and numerical methods that will enable simulations of drug actions on the electrophysiology of the human heart.

Such simulations will involve modelling of drug interactions at the molecular and cellular level, will extend current technology to enable prediction of the effects of those interactions on the dynamics of the whole heart, and will lead to an understanding of how genetic factors can be used to assess patient-specific risk profiles. This requires a multi-level systems approach, based on multi-scale, multi-physics methods, including computations on adaptive spatial grids and multi-grid time integration. Computations on realistic models at appropriate spatial and temporal scales are currently not feasible, so we will investigate new algorithms and their implementation on high-performance platforms, including a new generation of petaflop computers, to achieve 'faster than real-time' simulation.

These tools form part of the infrastructure required to simulate the physiology of major organ systems, thereby contributing to the goal of creating the Virtual Physiological Human (VPH) [ICT-2007.5.3]. The balanced team in this project, including founders of the Human Physiome Project, has decades of experience in the experimental study and modelling of the electrophysiology and mechanics of the heart, while pharmaceutical industry partners bring deep understanding of the mechanisms of drug actions. The results will demonstrate the value of the VPH initiative to fundamental scientific understanding of the heart, with major economic and clinical impacts through accelerated drug development, approval and use.

For further information, please visit:
http://www.vph-predict.eu

Project co-ordinator:
The Chancellor, Master and Scholars of the University of Oxford

Partners:

  • F. Hoffmann-La Roche AG
  • Szegedi Tudományegyetem
  • Fujitsu Laboratories of Europe Limited
  • Glaxo Smithkline Research and Development
  • Universidad Politécnica de Valencia
  • Centro di Ricerca, Sviluppo e Studi Superiori in Sardegna
  • Novartis Pharma AG
  • Aureus Pharma SA

Timetable: from 06/2008 – to 05/2011

Total cost: € 5.545.692

EC funding: € 4.100.000

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

Mobile Phone Data Helps Track Pathogen S…

A new way to map the spread and evolution of pathogens, and their responses to vaccines and antibiotics, will provide key insights to help predict and prevent future outbreaks. The...

AI Model to Improve Patient Response to …

A new artificial intelligence (AI) tool that can help to select the most suitable treatment for cancer patients has been developed by researchers at The Australian National University (ANU). DeepPT, developed...

Can AI Tell you if You Have Osteoporosis…

Osteoporosis is so difficult to detect in early stage it’s called the "silent disease." What if artificial intelligence could help predict a patient’s chances of having the bone-loss disease before...

Study Reveals Why AI Models that Analyze…

Artificial intelligence (AI) models often play a role in medical diagnoses, especially when it comes to analyzing images such as X-rays. However, studies have found that these models don’t always...

Think You're Funny? ChatGPT might b…

A study comparing jokes by people versus those told by ChatGPT shows that humans need to work on their material. The research team behind the study published on Wednesday, July 3...

Innovative, Highly Accurate AI Model can…

If there is one medical exam that everyone in the world has taken, it's a chest x-ray. Clinicians can use radiographs to tell if someone has tuberculosis, lung cancer, or...

New AI Approach Optimizes Antibody Drugs

Proteins have evolved to excel at everything from contracting muscles to digesting food to recognizing viruses. To engineer better proteins, including antibodies, scientists often iteratively mutate the amino acids -...

AI Speeds Up Heart Scans, Saving Doctors…

Researchers have developed a groundbreaking method for analysing heart MRI scans with the help of artificial intelligence (AI), which could save valuable NHS time and resources, as well as improve...

Researchers Customize AI Tools for Digit…

Scientists from Weill Cornell Medicine and the Dana-Farber Cancer Institute in Boston have developed and tested new artificial intelligence (AI) tools tailored to digital pathology - a rapidly growing field...

Young People Believe that AI is a Valuab…

Children and young people are generally positive about artificial intelligence (AI) and think it should be used in modern healthcare, finds the first-of-its-kind survey led by UCL and Great Ormond...